Key Points
- Insider sale: Well Daan Van sold 6,168 SOPHiA GENETICS shares at an average price of $7.63, generating $47,061.84. The transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving the insider with 338,884 shares.
- Financial performance: SOPHiA GENETICS reported quarterly revenue of $23.31 million, exceeding estimates, but its adjusted loss of $0.26 per share missed expectations. The company continues to post substantial negative margins and return on equity.
- Mixed analyst outlook: Analysts have issued three Buy, one Hold and one Sell rating, producing an overall “Hold” consensus and an average price target of $10.00, above the stock’s reported $7.86 opening price.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Well Van sold 6,168 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $7.63, for a total transaction of $47,061.84. Following the completion of the sale, the insider directly owned 338,884 shares of the company's stock, valued at approximately $2,585,684.92. This trade represents a 1.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
SOPHiA GENETICS Stock Performance
NASDAQ:SOPH opened at $7.86 on Tuesday. The firm's 50-day moving average is $7.08 and its 200-day moving average is $5.71. SOPHiA GENETICS SA has a 52-week low of $3.12 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market cap of $659.38 million, a price-to-earnings ratio of -6.83 and a beta of 0.98.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. Equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have commented on SOPH shares. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. HC Wainwright raised their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $10.00.
Get Our Latest Stock Analysis on SOPHiA GENETICS
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Maven Securities LTD acquired a new stake in SOPHiA GENETICS during the second quarter valued at approximately $866,000. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $9,809,000. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter worth approximately $1,772,000. 1492 Capital Management LLC acquired a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $973,000. Finally, Royce & Associates LP bought a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Institutional investors own 31.59% of the company's stock.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company's platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.
Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
